Company Overview and News

0
Standard Chartered PLC - Updates

2018-07-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
STAN 580001 STAB STAN STAC 2888 SCBFF

0
Copper — a metal with a history of predicting economic trouble — hits 1-year low, nears bear market

2018-07-19 cnbc
Copper prices reached their lowest levels in a year on Thursday, as concerns that a global trade war could strain global supply chains and slow down the global economy.
STAN 580001 STAB STAN STAC 2888 SCBFF

0
Virtual banking is set to shake up Hong Kong

2018-07-19 theedgemarkets
(July 19): Hong Kong, long a global leader in banking and finance, is bracing for the arrival of so-called virtual banks — financial institutions without physical branches where all transactions are online.
STAN 580001 STAB STAN STAC 2888 SCBFF

0
Virtual banking is set to shake up Hong Kong

2018-07-19 cnbc
Hong Kong, long a global leader in banking and finance, is bracing for the arrival of so-called virtual banks — financial institutions without physical branches where all transactions are online.
STAN 580001 STAB STAN STAC 2888 SCBFF

0
ASK Group targets $1 billion valuation in share sale

2018-07-17 livemint
Mumbai: ASK Group is aiming for a valuation of more than $1 billion as it looks to become the first investment and wealth management firm to launch an initial public offering (IPO), said three people aware of the development.
523405 STAN 580001 STAB STAN STAC 2888 SCBFF JMFINANCIL

0
Standard Chartered PLC - Updates

2018-07-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
STAN 580001 STAB STAN STAC 2888 SCBFF

0
RPT-INSIGHT-Moonwalking: South Korea's wage, hours policies backfire for jobless, low income workers

2018-07-17 reuters
SEOUL, July 17 (Reuters) - President Moon Jae-in wants South Koreans to work less and earn more – and to achieve that his government has hiked the minimum wage and slashed the maximum length of the working week. But Heo Jeong, who serves barley tea samples at a Lotte Mart store in Seoul, says she lost a third of her income as a result.
STAN 580001 STAB STAN STAC 2888 SCBFF LOTS

0
Moonwalking: South Korea's wage, hours policies backfire for jobless, low income workers

2018-07-17 theedgemarkets
SEOUL (July 17): President Moon Jae-in wants South Koreans to work less and earn more – and to achieve that his government has hiked the minimum wage and slashed the maximum length of the working week. But Heo Jeong, who serves barley tea samples at a Lotte Mart store in Seoul, says she lost a third of her income as a result.
STAN 580001 STAB STAN STAC 2888 SCBFF LOTS

0
Moonwalking: South Korea's wage, hours policies backfire for jobless, low income workers - Channel NewsAsia

2018-07-17 channelnewsasia
President Moon Jae-in wants South Koreans to work less and earn more – and to achieve that his government has hiked the minimum wage and slashed the maximum length of the working week. But Heo Jeong, who serves barley tea samples at a Lotte Mart store in Seoul, says she lost a third of her income as a result.
STAN 580001 STAB STAN STAC 2888 SCBFF LOTS

0
Moonwalking: South Korea's wage, hours policies backfire for jobless, low income workers

2018-07-17 reuters
SEOUL (Reuters) - President Moon Jae-in wants South Koreans to work less and earn more – and to achieve that his government has hiked the minimum wage and slashed the maximum length of the working week. But Heo Jeong, who serves barley tea samples at a Lotte Mart store in Seoul, says she lost a third of her income as a result.
STAN 580001 STAB STAN STAC 2888 SCBFF LOTS

0
Hong Kong regulator, banks launch blockchain-based trade finance platform

2018-07-17 theedgemarkets
HONG KONG (July 17): Hong Kong’s banking regulator and seven banks, including HSBC Holdings PLC and Standard Chartered PLC, on Tuesday said they will jointly launch a trade finance platform in September using blockchain technology.
HCS.PRB STAN DBSDY ATB HSNGF HCS 0011 HSB 0005 D05 HSNGY DBSDF STAB 580001 STAC SCBFF STAN 2888 HSEA HSEB HSBC.PRA HSBC HBCYF

0
Banks Are Facing a Squeeze From Trump's Trade War - Bloomberg

2018-07-17 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
HCS.PRB STAN HCS HSB 0005 580001 STAB STAN STAC 2888 SCBFF HSEA HSEB HSBC.PRA HSBC HBCYF

0
Southeast Asia’s economic growth could be trade war’s next casualty

2018-07-16 bworldonline
If a widening trade war wasn’t enough to contend with, a global wave of policy tightening, strong oil prices and domestic politics are also weighing on growth prospects for the region.
STAN 580001 STAB STAN STAC 2888 SCBFF

0
Banks facing squeeze from Trump's trade war

2018-07-16 malaymail
LONDON, July 16 — For banks that finance trade in Asia, the tariff war between the US and China couldn’t come at a worse time.
HCS.PRB STAN HCS HSB 0005 580001 STAB STAN STAC 2888 SCBFF HSEA HSEB HSBC.PRA HSBC HBCYF

0
South-east Asia's growth could be trade war's next casualty

2018-07-16 malaymail
SINGAPORE, July 16 — For South-east Asia’s biggest economies, 2018 wasn’t supposed to be like this.
STAN 580001 STAB STAN STAC 2888 SCBFF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: G84228157